Last reviewed · How we verify
ABR-215050, tasquinimod
ABR-215050, tasquinimod is a Immunomodulator Small molecule drug developed by Active Biotech AB. It is currently in Phase 2 development for Prostate cancer.
Tasquinimod is a quinoline-3-carboxamide derivative that modulates the immune system by targeting the S100A9 protein.
Tasquinimod is a quinoline-3-carboxamide derivative that modulates the immune system by targeting the S100A9 protein. Used for Prostate cancer.
At a glance
| Generic name | ABR-215050, tasquinimod |
|---|---|
| Sponsor | Active Biotech AB |
| Drug class | Immunomodulator |
| Target | S100A9 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Tasquinimod works by binding to S100A9, a protein involved in the regulation of immune responses. This binding leads to the activation of immune cells, such as macrophages and T cells, which can help to fight cancer cells. By modulating the immune system in this way, tasquinimod may help to slow the progression of cancer.
Approved indications
- Prostate cancer
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Abdominal pain
- Headache
Key clinical trials
- Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF) (PHASE1, PHASE2)
- Tasquinimod for the Treatment of Relapsed or Refractory Myeloma (PHASE1)
- Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition (PHASE1, PHASE2)
- Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (PHASE2)
- Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer (PHASE3)
- A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy (PHASE2)
- A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers (PHASE2)
- The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABR-215050, tasquinimod CI brief — competitive landscape report
- ABR-215050, tasquinimod updates RSS · CI watch RSS
- Active Biotech AB portfolio CI
Frequently asked questions about ABR-215050, tasquinimod
What is ABR-215050, tasquinimod?
How does ABR-215050, tasquinimod work?
What is ABR-215050, tasquinimod used for?
Who makes ABR-215050, tasquinimod?
What drug class is ABR-215050, tasquinimod in?
What development phase is ABR-215050, tasquinimod in?
What are the side effects of ABR-215050, tasquinimod?
What does ABR-215050, tasquinimod target?
Related
- Drug class: All Immunomodulator drugs
- Target: All drugs targeting S100A9
- Manufacturer: Active Biotech AB — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Prostate cancer
- Compare: ABR-215050, tasquinimod vs similar drugs
- Pricing: ABR-215050, tasquinimod cost, discount & access